Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43850   clinical trials with a EudraCT protocol, of which   7282   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Clinical non-inferiority study between Daflon® 1000 mg, one oral suspension in a sachet per day and Daflon 500® mg, 2 tablets daily after eight weeks of treatment in patients suffering from symptomatic Chronic Venous Disease (CVD). International, multicenter, double-blind, randomized, parallel group study.

    Due to the EudraCT – Results system being out of service between 31 July 2015 and 12 January 2016, these results have been published in compliance with revised timelines.
    Summary
    EudraCT number
    2012-003559-13
    Trial protocol
    SI   CZ   ES   SK  
    Global end of trial date
    15 Dec 2014

    Results information
    Results version number
    v1(current)
    This version publication date
    16 Apr 2016
    First version publication date
    16 Apr 2016
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    CL3-05682-105
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    U1111-1135-8530
    Sponsors
    Sponsor organisation name
    Institut de Recherche Internationales Servier (I.R.I.S)
    Sponsor organisation address
    50 rue Carnot, Suresnes, France, 92284
    Public contact
    Clinical Studies Department, Institut de Recherches Internationales Servier, +33 155 72 43 66, clinicaltrials@servier.com
    Scientific contact
    Clinical Studies Department, Institut de Recherches Internationales Servier, +33 155 72 43 66, clinicaltrials@servier.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    15 Dec 2014
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    15 Dec 2014
    Global end of trial reached?
    Yes
    Global end of trial date
    15 Dec 2014
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To demonstrate the clinical non inferiority of efficacy between Daflon® 1000 mg (1 sachet per day) and Daflon® 500 mg (2 tablets per day), in improving lower limb discomfort assessed by a 10 cm visual analogue scale (VAS) after eight weeks of treatment in patients suffering from CVD
    Protection of trial subjects
    This study was conducted in accordance with Good Clinical Practice standards, ethical principles stated in the Declaration of Helsinki and applicable regulatory requirements. After the subject has ended his/her participation in the trial, the investigator provided appropriate medication and/or arranged access to appropriate care for the patient.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    22 Jul 2013
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Argentina: 146
    Country: Number of subjects enrolled
    Brazil: 65
    Country: Number of subjects enrolled
    Malaysia: 3
    Country: Number of subjects enrolled
    Mexico: 48
    Country: Number of subjects enrolled
    Romania: 194
    Country: Number of subjects enrolled
    Russian Federation: 255
    Country: Number of subjects enrolled
    Czech Republic: 94
    Country: Number of subjects enrolled
    Slovakia: 94
    Country: Number of subjects enrolled
    Slovenia: 53
    Country: Number of subjects enrolled
    Spain: 67
    Country: Number of subjects enrolled
    Thailand: 47
    Country: Number of subjects enrolled
    Turkey: 51
    Country: Number of subjects enrolled
    Vietnam: 22
    Worldwide total number of subjects
    1139
    EEA total number of subjects
    502
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    1050
    From 65 to 84 years
    89
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    Male or female outpatient aged between 20 and 75 years old (inclusive), suffering from primary chronic venous disease, with lower limb discomfort ≥ 4 cm on the VAS scale and at least leg pain ≥ 3 cm on the VAS scale and belonging to the Clinical Etiological Anatomic Pathophysiologic (CEAP) class C0s to C4s on the most affected leg.

    Period 1
    Period 1 title
    Double-blind treatment period (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    MPFF sachet 1000 mg o.d.
    Arm description
    -
    Arm type
    Experimental

    Investigational medicinal product name
    MPFF 1000 mg sachet
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Oral suspension in sachet
    Routes of administration
    Oral use
    Dosage and administration details
    One sachet taken daily (in the morning) per os.

    Arm title
    MPFF tablet 500 mg b.i.d.
    Arm description
    -
    Arm type
    Active comparator

    Investigational medicinal product name
    MPFF 500 mg tablet
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    2 tablets daily (one at midday and one in the evening) taken per os

    Number of subjects in period 1
    MPFF sachet 1000 mg o.d. MPFF tablet 500 mg b.i.d.
    Started
    571
    568
    Completed
    540
    536
    Not completed
    31
    32
         Adverse event, non-fatal
    6
    9
         Lost to follow-up
    -
    1
         Non-medical reason
    9
    8
         Lack of efficacy
    1
    -
         Protocol deviation
    15
    14

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    MPFF sachet 1000 mg o.d.
    Reporting group description
    -

    Reporting group title
    MPFF tablet 500 mg b.i.d.
    Reporting group description
    -

    Reporting group values
    MPFF sachet 1000 mg o.d. MPFF tablet 500 mg b.i.d. Total
    Number of subjects
    571 568 1139
    Age categorical
    Units: Subjects
        Adults (18-64 years)
    534 516 1050
        From 65-84 years
    37 52 89
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    45.9 ± 11.9 46.1 ± 12.2 -
    Gender categorical
    Units: Subjects
        Female
    488 489 977
        Male
    83 79 162

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    MPFF sachet 1000 mg o.d.
    Reporting group description
    -

    Reporting group title
    MPFF tablet 500 mg b.i.d.
    Reporting group description
    -

    Subject analysis set title
    Full Analysis Set
    Subject analysis set type
    Full analysis
    Subject analysis set description
    All patients of the Randomised Set having taken at least one dose of IMP and having a value at baseline and at least one post-baseline value for the lower limb discomfort assessed by a VAS scale.

    Primary: Lower limb discomfort (VAS)

    Close Top of page
    End point title
    Lower limb discomfort (VAS)
    End point description
    On the VAS scale: 0 cm = no discomfort and 10 cm = extreme discomfort
    End point type
    Primary
    End point timeframe
    Evaluation at selection, W0, W2, W4 and W8. The primary analysis was the change from baseline to last post-baseline value up to W8 visit
    End point values
    MPFF sachet 1000 mg o.d. MPFF tablet 500 mg b.i.d.
    Number of subjects analysed
    568
    557
    Units: cm
        arithmetic mean (standard deviation)
    -3.272 ± 2.419
    -3.33 ± 2.404
    Statistical analysis title
    Non-inferiority analysis
    Comparison groups
    MPFF sachet 1000 mg o.d. v MPFF tablet 500 mg b.i.d.
    Number of subjects included in analysis
    1125
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority [1]
    P-value
    < 0.0001
    Method
    ANCOVA
    Confidence interval
    Notes
    [1] - Non-inferiority limit = 1 cm. One-sided type I error rate = 0.025. Analysis included the fixed, categorical effects of treatment and centre, as well as the continous, fixed covariate of baseline.

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Adverse events were reported all over the study.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    17.0
    Reporting groups
    Reporting group title
    MPFF sachet 1000 mg o.d.
    Reporting group description
    -

    Reporting group title
    MPFF tablet 500 mg b.i.d.
    Reporting group description
    -

    Serious adverse events
    MPFF sachet 1000 mg o.d. MPFF tablet 500 mg b.i.d.
    Total subjects affected by serious adverse events
         subjects affected / exposed
    2 / 568 (0.35%)
    3 / 568 (0.53%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    0
    0
    Injury, poisoning and procedural complications
    Incisional hernia
         subjects affected / exposed
    1 / 568 (0.18%)
    0 / 568 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nervous system disorders
    Cerebrovascular insufficiency
         subjects affected / exposed
    1 / 568 (0.18%)
    0 / 568 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Syncope
         subjects affected / exposed
    1 / 568 (0.18%)
    0 / 568 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Face oedema
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Dysphagia
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Reproductive system and breast disorders
    Ovarian cyst
         subjects affected / exposed
    1 / 568 (0.18%)
    0 / 568 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Uterine adhesions
         subjects affected / exposed
    1 / 568 (0.18%)
    0 / 568 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Asthma
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    Rash
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Swelling face
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Urticaria
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Sepsis
         subjects affected / exposed
    1 / 568 (0.18%)
    0 / 568 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 0.1%
    Non-serious adverse events
    MPFF sachet 1000 mg o.d. MPFF tablet 500 mg b.i.d.
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    72 / 568 (12.68%)
    75 / 568 (13.20%)
    Vascular disorders
    Hypertension
         subjects affected / exposed
    1 / 568 (0.18%)
    0 / 568 (0.00%)
         occurrences all number
    1
    0
    Hypertensive crisis
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Phlebitis superficial
         subjects affected / exposed
    1 / 568 (0.18%)
    0 / 568 (0.00%)
         occurrences all number
    1
    0
    Surgical and medical procedures
    Carpal tunnel decompression
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    General disorders and administration site conditions
    Chills
         subjects affected / exposed
    1 / 568 (0.18%)
    0 / 568 (0.00%)
         occurrences all number
    1
    0
    Reproductive system and breast disorders
    Dysmenorrhoea
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Genital paraesthesia
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Menstruation delayed
         subjects affected / exposed
    1 / 568 (0.18%)
    0 / 568 (0.00%)
         occurrences all number
    1
    0
    Respiratory, thoracic and mediastinal disorders
    Epistaxis
         subjects affected / exposed
    1 / 568 (0.18%)
    0 / 568 (0.00%)
         occurrences all number
    1
    0
    Psychiatric disorders
    Insomnia
         subjects affected / exposed
    0 / 568 (0.00%)
    2 / 568 (0.35%)
         occurrences all number
    0
    3
    Anxiety
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Investigations
    Weight increased
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Injury, poisoning and procedural complications
    Fall
         subjects affected / exposed
    2 / 568 (0.35%)
    1 / 568 (0.18%)
         occurrences all number
    2
    1
    Ligament sprain
         subjects affected / exposed
    2 / 568 (0.35%)
    1 / 568 (0.18%)
         occurrences all number
    2
    1
    Contusion
         subjects affected / exposed
    2 / 568 (0.35%)
    0 / 568 (0.00%)
         occurrences all number
    2
    0
    Arthropod bite
         subjects affected / exposed
    1 / 568 (0.18%)
    0 / 568 (0.00%)
         occurrences all number
    1
    0
    Excoriation
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Road traffic accident
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Soft tissue injury
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Traumatic haematoma
         subjects affected / exposed
    1 / 568 (0.18%)
    0 / 568 (0.00%)
         occurrences all number
    1
    0
    Nervous system disorders
    Headache
         subjects affected / exposed
    5 / 568 (0.88%)
    7 / 568 (1.23%)
         occurrences all number
    5
    8
    Paraesthesia
         subjects affected / exposed
    1 / 568 (0.18%)
    3 / 568 (0.53%)
         occurrences all number
    1
    3
    Dizziness
         subjects affected / exposed
    0 / 568 (0.00%)
    2 / 568 (0.35%)
         occurrences all number
    0
    2
    Hypoaesthesia
         subjects affected / exposed
    1 / 568 (0.18%)
    1 / 568 (0.18%)
         occurrences all number
    1
    1
    Somnolence
         subjects affected / exposed
    0 / 568 (0.00%)
    2 / 568 (0.35%)
         occurrences all number
    0
    2
    Blood and lymphatic system disorders
    Lymph node pain
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Gastrointestinal disorders
    Diarrhoea
         subjects affected / exposed
    5 / 568 (0.88%)
    7 / 568 (1.23%)
         occurrences all number
    5
    7
    Nausea
         subjects affected / exposed
    7 / 568 (1.23%)
    5 / 568 (0.88%)
         occurrences all number
    7
    5
    Abdominal pain upper
         subjects affected / exposed
    7 / 568 (1.23%)
    2 / 568 (0.35%)
         occurrences all number
    7
    2
    Gastritis
         subjects affected / exposed
    0 / 568 (0.00%)
    4 / 568 (0.70%)
         occurrences all number
    0
    4
    Dyspepsia
         subjects affected / exposed
    2 / 568 (0.35%)
    3 / 568 (0.53%)
         occurrences all number
    2
    4
    Abdominal discomfort
         subjects affected / exposed
    3 / 568 (0.53%)
    0 / 568 (0.00%)
         occurrences all number
    3
    0
    Constipation
         subjects affected / exposed
    2 / 568 (0.35%)
    0 / 568 (0.00%)
         occurrences all number
    2
    0
    Abdominal distension
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Abdominal pain
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Colitis
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Defaecation urgency
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Dental caries
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Dry mouth
         subjects affected / exposed
    1 / 568 (0.18%)
    0 / 568 (0.00%)
         occurrences all number
    1
    0
    Epigastric discomfort
         subjects affected / exposed
    1 / 568 (0.18%)
    0 / 568 (0.00%)
         occurrences all number
    1
    0
    Flatulence
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Gastrooesophageal reflux disease
         subjects affected / exposed
    1 / 568 (0.18%)
    0 / 568 (0.00%)
         occurrences all number
    1
    0
    Gingival bleeding
         subjects affected / exposed
    1 / 568 (0.18%)
    0 / 568 (0.00%)
         occurrences all number
    1
    0
    Haemorrhoidal haemorrhage
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Haemorrhoids
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    2
    Hyperchlorhydria
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Irritable bowel syndrome
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Toothache
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Vomiting
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Hepatobiliary disorders
    Biliary colic
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Hepatitis acute
         subjects affected / exposed
    1 / 568 (0.18%)
    0 / 568 (0.00%)
         occurrences all number
    1
    0
    Skin and subcutaneous tissue disorders
    Acne
         subjects affected / exposed
    0 / 568 (0.00%)
    2 / 568 (0.35%)
         occurrences all number
    0
    2
    Dermatitis allergic
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Ingrowing nail
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Pruritus
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Pruritus generalised
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Rash
         subjects affected / exposed
    1 / 568 (0.18%)
    0 / 568 (0.00%)
         occurrences all number
    1
    0
    Musculoskeletal and connective tissue disorders
    Muscle spasms
         subjects affected / exposed
    5 / 568 (0.88%)
    0 / 568 (0.00%)
         occurrences all number
    5
    0
    Arthralgia
         subjects affected / exposed
    2 / 568 (0.35%)
    1 / 568 (0.18%)
         occurrences all number
    2
    1
    Back pain
         subjects affected / exposed
    2 / 568 (0.35%)
    0 / 568 (0.00%)
         occurrences all number
    2
    0
    Pain in extremity
         subjects affected / exposed
    1 / 568 (0.18%)
    1 / 568 (0.18%)
         occurrences all number
    2
    1
    Muscle twitching
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Musculoskeletal pain
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Osteoarthritis
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Tenosynovitis
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Muscle contracture
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Infections and infestations
    Nasopharyngitis
         subjects affected / exposed
    3 / 568 (0.53%)
    5 / 568 (0.88%)
         occurrences all number
    3
    5
    Pharyngitis
         subjects affected / exposed
    2 / 568 (0.35%)
    4 / 568 (0.70%)
         occurrences all number
    2
    4
    Gastroenteritis
         subjects affected / exposed
    4 / 568 (0.70%)
    0 / 568 (0.00%)
         occurrences all number
    4
    0
    Influenza
         subjects affected / exposed
    2 / 568 (0.35%)
    2 / 568 (0.35%)
         occurrences all number
    2
    2
    Upper respiratory tract infection
         subjects affected / exposed
    3 / 568 (0.53%)
    1 / 568 (0.18%)
         occurrences all number
    3
    1
    Urinary tract infection
         subjects affected / exposed
    2 / 568 (0.35%)
    2 / 568 (0.35%)
         occurrences all number
    2
    2
    Bronchitis
         subjects affected / exposed
    1 / 568 (0.18%)
    1 / 568 (0.18%)
         occurrences all number
    1
    1
    Respiratory tract infection viral
         subjects affected / exposed
    2 / 568 (0.35%)
    0 / 568 (0.00%)
         occurrences all number
    2
    0
    Rhinitis
         subjects affected / exposed
    1 / 568 (0.18%)
    1 / 568 (0.18%)
         occurrences all number
    1
    1
    Sinusitis
         subjects affected / exposed
    2 / 568 (0.35%)
    0 / 568 (0.00%)
         occurrences all number
    2
    0
    Acute tonsillitis
         subjects affected / exposed
    1 / 568 (0.18%)
    0 / 568 (0.00%)
         occurrences all number
    1
    0
    Conjunctivitis
         subjects affected / exposed
    1 / 568 (0.18%)
    0 / 568 (0.00%)
         occurrences all number
    1
    0
    Cystitis
         subjects affected / exposed
    1 / 568 (0.18%)
    0 / 568 (0.00%)
         occurrences all number
    1
    0
    Diarrhoea infectious
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Myringitis
         subjects affected / exposed
    1 / 568 (0.18%)
    0 / 568 (0.00%)
         occurrences all number
    1
    0
    Oral herpes
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Otitis media
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Respiratory tract infection
         subjects affected / exposed
    1 / 568 (0.18%)
    0 / 568 (0.00%)
         occurrences all number
    1
    0
    Soft tissue infection
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Tinea versicolour
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Tracheitis
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1
    Viral rhinitis
         subjects affected / exposed
    0 / 568 (0.00%)
    1 / 568 (0.18%)
         occurrences all number
    0
    1

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    25 Nov 2013
    Applicable in all centres and concerned mainly: - Deletion of urinary proteinuria test; blood biochemistry testing was maintained to ensure detection of abnormality in renal dysfunction. - Reduce to one measurement, instead of three, of sitting blood pressure, considered as reliable enough in blood pressure assessment. - Change to one month before the selection of the patient, the planned period of 3 months without compression and for non-authorized pharmacological treatment. - Deletion of the detailed mention regarding Ankle Brachial Pressure Index for assessment of peripheral arterial occlusive disease. - Clarification of the definition and wording of following non-selection criteria: “on going deep or superficial vein thrombosis” and “Evidence of cancer”. - Precision regarding non-compliance (protocol deviation). - Deletion of the question 8a in CIVIQ-20 in accordance with Pr Launois (author of CIVIQ-20). Only the question 8b was taken in account for the questionnaire analysis for the study. Indeed, question 8a was restrictive to car use which was not common in all countries.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 19 20:22:47 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA